SS Innovations International (NASDAQ:SSII) Trading Up 14.1% After Insider Buying Activity

Shares of SS Innovations International, Inc. (NASDAQ:SSII) rose 14.1% during trading on Wednesday following insider buying activity. The company traded as high as $5.10 and last traded at $5.0450. Approximately 53,240 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 99,295 shares. The stock had previously closed at $4.42.

Specifically, CEO Srivastava Sudhir acquired 498,753 shares of the company’s stock in a transaction dated Friday, March 6th. The stock was acquired at an average cost of $4.01 per share, with a total value of $1,999,999.53. Following the purchase, the chief executive officer directly owned 109,851,767 shares in the company, valued at approximately $440,505,585.67. This trade represents a 0.46% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Timothy P. Adams bought 300,000 shares of SS Innovations International stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $3.99 per share, for a total transaction of $1,197,000.00. Following the purchase, the director owned 5,331,902 shares in the company, valued at $21,274,288.98. This represents a 5.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In related news, Director Frederic H. Moll bought 501,253 shares of the stock in a transaction on Friday, March 6th. The shares were purchased at an average price of $3.99 per share, for a total transaction of $1,999,999.47. Following the acquisition, the director owned 10,775,485 shares in the company, valued at $42,994,185.15. This represents a 4.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SS Innovations International in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

More SS Innovations International News

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: CEO Srivastava purchased 498,753 shares (~$2.0M at ~$4.01), a meaningful insider buy that signals management confidence. SEC filing: Srivastava purchase
• Positive Sentiment: Director Timothy P. Adams bought 300,000 shares (~$1.2M at $3.99), increasing his stake — reinforces insider support. SEC filing: Adams purchase
• Positive Sentiment: Vice‑Chair Dr. Frederic H. Moll acquired 501,253 shares (~$2.0M at $3.99), adding to insider participation. SEC filing: Moll purchase
• Positive Sentiment: Company released Q4 and full‑year 2025 results showing strong growth in SSi Mantra installations, procedures and revenue — supports the growth narrative for device adoption. GlobeNewswire: Q4/FY2025 results
• Positive Sentiment: SS Innovations completed an $18.6M private placement to fund U.S./EU expansion and working capital — provides near‑term cash to support commercialization efforts. GlobeNewswire: Private placement
• Neutral Sentiment: Some institutional investors have added positions recently, which could support liquidity and longer‑term demand but may not alter near‑term volatility. QuiverQuant: ownership/placement summary
• Negative Sentiment: Company reported a small quarterly loss (EPS $(0.01)) with a negative net margin (~‑32.1%) and negative ROE (~‑34.1%), underscoring that profitability is still distant. MarketBeat: earnings summary
• Negative Sentiment: The private placement issued ~5.77M new shares and included unregistered securities/warrants to a FINRA firm — this raises dilution and registration/liquidity concerns. GlobeNewswire: private placement terms
• Negative Sentiment: Regulatory timing (FDA 510(k) review expected mid‑2026 and CE efforts) creates execution risk; outcomes and timing will strongly affect the share path. GlobeNewswire: regulatory timeline
• Negative Sentiment: Analyst coverage is limited and includes a recent Sell (Weiss Ratings) — a reminder of continued skepticism among some research shops. Weiss Ratings: research note

SS Innovations International Price Performance

The firm has a market cap of $988.32 million and a price-to-earnings ratio of -101.70. The business’s 50-day moving average price is $4.82 and its two-hundred day moving average price is $6.05.

SS Innovations International (NASDAQ:SSII) last announced its earnings results on Tuesday, March 10th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $14.53 million for the quarter. SS Innovations International had a negative return on equity of 34.13% and a negative net margin of 32.10%.

Institutional Investors Weigh In On SS Innovations International

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. acquired a new position in SS Innovations International in the third quarter valued at $56,000. Envestnet Asset Management Inc. acquired a new stake in SS Innovations International in the 3rd quarter worth about $71,000. Jane Street Group LLC acquired a new stake in SS Innovations International in the 4th quarter worth about $63,000. IFC & Insurance Marketing Inc. purchased a new stake in SS Innovations International in the 4th quarter valued at about $64,000. Finally, Goldman Sachs Group Inc. purchased a new stake in SS Innovations International in the 4th quarter valued at about $68,000.

SS Innovations International Company Profile

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.